Truist analyst Richard Newitter lowered the firm’s price target on Integra LifeSciences to $26 from $32 and keeps a Hold rating on the shares. The analyst cites the company “big” guidance cut for the second half of the year while noting that there is still see too much uncertainty around given the ongoing execution risk and a potentially prolonged share recapture situation with so many products off the market. Truist is also cutting its Integra LifeScience FY24 EBITDA view to $320M from $381M and its FY25 view to $357M from $415M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences lowers FY24 adj EPS view to $2.41-$3.57 from $3.01-$3.11
- Integra LifeSciences reports Q2 adjusted EPS 63c, consensus 62c
- IART Earnings this Week: How Will it Perform?
- Integra LifeSciences price target raised to $32 from $25 at Truist
- Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024